Is Arcturus Therapeutics Holdings Inc (ARCT) overvalued? · rev $152.3M
Arcturus Therapeutics Holdings Inc (ARCT) is a biotechnology company listed on US.
This page asks whether Arcturus Therapeutics Holdings Inc (ARCT) looks expensive on cached numbers — not a short thesis.
Latest reported ARCT revenue for 2024-12-31 was $152.3M. Net income was -$80.9M. Revenue was down 8.7% from 2023-12-31 to 2024-12-31. ARCT currently screens at market cap $369.4M.
ARCT currently screens at market cap $369.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ARCT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ARCT stock page for the full model, not this heading.
Not investment advice.